Tharimmune

QV Bioelectronics is dedicated to improving the lives of brain tumor patients by developing a unique electric field therapy implant called GRACE, in collaboration with leading neurosurgeons in the UK. The goal is to increase life expectancy without compromising quality of life for patients with glioblastoma, a particularly difficult-to-treat brain tumor. Co-founder Dr. Richard Fu, along with Dr. Chris Bullock, created GRACE to address the lack of effective treatments for this type of tumor. The company has received significant financial support and investments to further develop their innovative solution and has assembled a team of experts with years of experience in bringing GRACE to the clinic.

Anzen Industries focuses on biotech innovation, engineering molecular resilience by stabilizing enzymes for industrial reactions.

Tiziana Life Sciences plc is a biotechnology company based in the UK that specializes in discovering and developing new molecules for treating human diseases in the fields of oncology and immunology. The company is currently focused on milciclib, a compound that inhibits specific enzymes known as cyclin-dependent kinases (CDK) and other protein kinases involved in cell division. Milciclib is currently in phase II clinical trials for treating epithelial thymic carcinoma and/or thymoma in patients who have undergone chemotherapy, and the company has also filed an Investigational New Drug (IND) application to conduct an exploratory trial for Hepatic Cellular Carcinoma (HCC).

At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.

Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.

Engitix is using its proprietary human organ decellularisation technology to develop tissue engineered products for application in regenerative medicine and drug-target research. Engitix’ core expertise is treatment and research of liver disease using its proprietary technologies for human extra-cellular matrix (ECM) scaffolds and 3D spheroids for bioartificial liver devices. The scaffold technology is applicable to other organs and disease aetiologies including pancreatic and intestine scaffold products.

Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting the most debilitating aspects of the neurological, metabolic and retinal dysfunctions.

Biomarx specializes in automated genomic diagnostics. The company develops rapid, low-cost liquid biopsy solutions to enable early lung cancer detection and replace traditional genome sequencing in clinical settings.

GlycanAge was founded to accelerate the shift from reactive to proactive health, for which we need biomarkers. Changing more than a decade before CVD events, hypertension, insulin resistance, etc. glycans are the dark horse in the race to longevity and key to unlocking this multi-trillion dollar industry. To enable that, GlycanAge has packaged a best-in-class solution into a simple take-home test.

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

Celtic Renewables is a biotechnology startup that was established to bring to market a process for creating an advanced biofuel, along with other valuable sustainable products, using the waste products of biological industries. The company's primary focus is on the Scottish Malt Whisky industry, which is a valuable resource for developing biobutanol. This biobutanol can serve as a sustainable alternative to gasoline and diesel, compatible with any car engine without requiring modifications. Founded by Martin Tangney in 2011, Celtic Renewables is headquartered in Edinburgh, UK.

Connection Therapeutics takes part in adapting drug revelation and improvement. It use human hereditary qualities and clinical omics information and uses patient-inferred tissue tests with practical genomics interventional trials to distinguish, approve and indict remedial projects.